The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1245 Weight Loss articles
From celebrity endorsements to GLP-1 weight loss drugs, peptides are everywhere. But what exactly are they, and can they deliver on their promises for skin health, longevity, and more? This article dives into the science, the trends, and the risks.
Curious about how long Ozempic, Wegovy, Mounjaro, or other GLP-1 medications stay in your system after your last dose? This comprehensive guide explores the science behind their elimination and what factors influence their duration.
The UK's MHRA has approved Wegovy (semaglutide) for treating MASH, a significant step forward for patients with metabolic-associated steatohepatitis and liver fibrosis. This article delves into the details of this approval, the drug's mechanism, and its implications.
Discover how GLP-1 medications are impacting more than just physical health, influencing career opportunities and personal relationships for women in a remarkable new study.
Peptides are the newest buzzword in health and beauty, promising everything from wrinkle reduction to profound weight loss. But does the science actually back up the claims, and are they safe?
Canada's Health Department has cleared Apotex's Svemia, marking a major milestone for generic semaglutide availability and weight loss treatment access.
For years, Medicare coverage for GLP-1 medications like Ozempic and Wegovy was strictly limited to diabetes management. A significant shift is underway, however, as a new 'Bridge' program opens doors for weight loss coverage, albeit with specific requirements and nuances that patients must navigate.
New research sheds light on the neuropsychiatric effects of popular weight loss medications like semaglutide and tirzepatide. Discover how these treatments may influence anxiety, depression, and other mental health outcomes.
For the first time, Medicare is expanding access to GLP-1 medications for weight loss through a new pilot program. Starting July 1, eligible beneficiaries can access popular drugs like Wegovy and Zepbound for a $50 monthly copay. This groundbreaking initiative aims to make these life-changing treatments more accessible, but understanding the specifics is crucial.
